LB Pharmaceuticals Inc 2026年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period ended March 31, 2026OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period from ______ to _________Commission File Number: 001-42831 LB Pharmaceuticals Inc (Exact Name of Registrant as Specified in its Charter) 81-1854347(I.R.S. EmployerIdentification No.) Registrant’s telephone number, including area code: (212) 605-0300 Securities registered pursuant to Section 12(b) of the Act: Title of each classTradingSymbol(s)Name of each exchange on which registeredCommon Stock, $0.0001 par valueLBRXThe Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filingrequirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit suchfiles).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒Emerging growth company☒ Accelerated filer☐Smaller reporting company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ The number of shares of Registrant’s Common Stock outstanding as of May 7, 2026 was 28,676,652. Table of Contents Special Note Regarding Forward-Looking StatementsiiRisk Factors Summaryv PART I.FINANCIAL INFORMATION Item 1.Financial Statements (Unaudited)1Condensed Balance Sheets as of March 31, 2026 and December 31, 20251Condensed Statements of Operations for the Three Months Ended March 31, 2026 and 20252Condensed Statements of Comprehensive Loss for the Three Months Ended March 31, 2026 and 20253Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) forthe Three Months Ended March 31, 2026 and 20254Condensed Statements of Cash Flows for the Three Months Ended March 31, 2026 and 20255Notes to Condensed Financial Statements6Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations19Item 3.Quantitative and Qualitative Disclosures About Market Risk28Item 4.Controls and Procedures28 PART II.OTHER INFORMATION Item 1.Legal Proceedings30Item 1A.Risk Factors30Item 2.Unregistered Sales of Equity Securities and Use of Proceeds85Item 3.Defaults Upon Senior Securities85Item 4.Mine Safety Disclosures85Item 5.Other Information85Item 6.Exhibits86Signatures87 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report contains express or implied forward-looking statements within the meaning of the Private SecuritiesLitigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E ofthe Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements are based on our management’s beliefand assumptions and on information currently available to our management. Although we believe that the expectations reflected inthese forward-looking statements are reasonable, these statements relate to future events or our future operational or financialperformance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performanceor achievements to be materially different from any future results, performance or achievements expressed or implied by theseforward-looking statements. Forward-looking statements in this Quarterly Report on Form 10-Q include, but are not limited to,statements about: •the initiation, timing, progress, potential registrational quality, and results of our research and development programs,preclinical studies, any clinical trials, Investigational New Drug, or IND, New Drug Applications, or NDAs, and otherregulatory submissions;•the ability of our approach to reproducibly predict treatment outcomes for LB-102 amongst identified patient populationsand achieve clinical success;•the timing of and costs involved in obtain